Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Ceribell focuses on making electroencephalography accessible, efficient, and cost-effective.
Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Forge Biologics is a gene therapy development engine, enabling access to life changing gene therapy programs.
Empatica is an affective computing company focused on human data analytics.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
American Express Global Corporate Travel Advisors provides end-to-end corporate travel and meetings program management.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
Somatus is a healthcare company that partners with health plans, health systems, nephrology, and primary care groups.
Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Tasso is a Medical innovation company changing the way diagnostics are delivered
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 30 different industry categories.
Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post-IPO Equity round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include Ceribell, Point Biopharma, Forge Biologics, Empatica, Achilles Therapeutics. These companies were founded in 2020 or later.